Healthcare
Scinai Immunotherapeutics Ltd.(SCNI)
Live Price
Offline$0.331
+1.85% today
1Y Change
-81.55%
Window
Jun 23, 2025 β Jun 5, 2026
- Market Cap
- β
- Revenue Growth
- +99.2%
- EPS Growth
- -160.0%
- Dividend Yield
- 0.0%
Coverage: 240 bars Β· Jun 23, 2025 β Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scinai Immunotherapeutics Ltd. (SCNI) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.33 and down 81.6% across the available one-year price window (Jun 23, 2025 β Jun 5, 2026). Baseline metrics include revenue growth of +99.2%, EPS growth of -160.0%, a dividend yield of 0.0%. What stands out right now is revenue +99.2%, EPS -160.0%, free cash flow +4.6% with operating margin -574.0% and ROIC -72.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SCNI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+99.2% vs +7.6% peer median
Operating Margin
Below sector median
-574.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +99.2% and EPS is at -160.0%, with operating margin around -574.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 7, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | β | +4.6% | -1.5% | -24.1% |
2025 Dec 2, 2025 | β | +11.7% | +20.4% | -29.1% |
2025 Sep 2, 2025 | β | +4.5% | -1.9% | -17.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCNI
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
SCNI Max Drawdown
-83.64%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SCNI and SPY.
Company Overview
Scinai Immunotherapeutics Ltd.
NASDAQ Capital Market
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center GΓΆttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
- Leadership
- Amir Reichman
- IPO Date
- May 11, 2015
- Employees
- 31
- Street Address
- Jerusalem BioPark Building
- Mailing
- Jerusalem
- Region
- Jerusalem, IL
- Reporting Currency
- USD
- Investor Line
- 972 8 930 2529
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 0.7
- Price/Book
- 0.2
Growth
- Revenue
- +99.2%
- EPS
- -160.0%
- Free Cash Flow
- +4.6%
Profitability
- Gross Margin
- -201.8%
- Operating Margin
- -574.0%
- Net Margin
- -632.2%
- ROE
- -98.3%
- ROIC
- -72.7%
Balance Sheet
- Debt/Equity
- 0.28
- Current Ratio
- 1.30
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.